We are live on ! Find out more
ASBP

Aspire Biopharma
ASBP

59 hedge funds and large institutions have $260M invested in Aspire Biopharma in 2022 Q3 according to their latest regulatory filings, with 11 funds opening new positions, 7 increasing their positions, 9 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

175% more first-time investments, than exits

New positions opened: 11 | Existing positions closed: 4

13% more funds holding

Funds holding: 52 → 59 (+7)

8% more capital invested

Capital invested by funds: $241M → $260M (+$18.9M)

0% more ownership

Funds ownership: 0.07% → 0.07% (+0%)

22% less repeat investments, than reductions

Existing positions increased: 7 | Existing positions reduced: 9

Holders
59
Holders Change
+7
Holders Change %
+13.46%
% of All Funds
1.02%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
11
Increased
7
Reduced
9
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
HCM
Highbridge Capital Management
New York
+$8.73M
2
Goldman Sachs
Goldman Sachs
New York
+$4.55M
3
MF
Magnetar Financial
Illinois
+$4M
4
SCM
Shaolin Capital Management
Florida
+$2.51M
5
PC
Periscope Capital
Ontario, Canada
+$2.29M

Top Sellers

Rank Fund Capital Flow
1
AA
AQR Arbitrage
Connecticut
-$4.56M
2
WAM
Wolverine Asset Management
Illinois
-$3.67M
3
HI
HBK Investments
Texas
-$2.99M
4
CCM
Context Capital Management
California
-$2.52M
5
Verition Fund Management
Verition Fund Management
Connecticut
-$2.02M
Name Holding Trade Value Shares
Change 		Change in
Stake
GCL
1
Glazer Capital LLC
New York
$21.4M +$700K +58 +3%
Adage Capital Partners
2
Adage Capital Partners
Massachusetts
$21.3M – – –
HCM
3
Highbridge Capital Management
New York
$20.9M +$8.73M +723 +73%
SCM
4
Saba Capital Management
New York
$19.9M – – –
Millennium Management
5
Millennium Management
New York
$11.9M +$736K +61 +7%
SC
6
Sculptor Capital
New York
$11.7M – – –
HSBC Holdings
7
HSBC Holdings
United Kingdom
$11.7M – – –
PC
8
Periscope Capital
Ontario, Canada
$9.78M +$2.29M +190 +31%
AA
9
AQR Arbitrage
Connecticut
$8.99M -$4.56M -378 -34%
Verition Fund Management
10
Verition Fund Management
Connecticut
$7.1M -$2.02M -167 -22%
Barclays
11
Barclays
United Kingdom
$7.1M – – –
KC
12
Kepos Capital
New York
$6.84M – – –
FTCM
13
First Trust Capital Management
Illinois
$6.79M – – –
LA
14
Linden Advisors
New York
$6.59M – – –
Two Sigma Investments
15
Two Sigma Investments
New York
$6.34M – – –
TCA
16
Taconic Capital Advisors
New York
$6.08M – – –
MF
17
Magnetar Financial
Illinois
$5.37M +$4M +331 +301%
CF
18
Cantor Fitzgerald
New York
$5.07M – – –
Goldman Sachs
19
Goldman Sachs
New York
$4.59M +$4.55M +377 New
WAM
20
Wolverine Asset Management
Illinois
$4.18M -$3.67M -304 -47%
Marshall Wace
21
Marshall Wace
United Kingdom
$4.09M +$12.1K +1 +0.3%
Balyasny Asset Management
22
Balyasny Asset Management
Illinois
$4.08M – – –
D.E. Shaw & Co
23
D.E. Shaw & Co
New York
$4.06M – – –
SRCM
24
Sage Rock Capital Management
New York
$3.62M – – –
RCM
25
Radcliffe Capital Management
Pennsylvania
$3.04M – – –
1
2 3

ASBP Hedge Fund Activity: Q3 2022 in Review

59 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Aspire Biopharma (ASBP) for Q3 2022, worth a combined $260M — up 7.8% from $241M a quarter earlier.

Buyers outnumbered sellers: 11 funds opened new ASBP positions and 4 closed out — a net gain of 7 holders — while 7 added to existing stakes and 9 trimmed.

The largest buyer was Highbridge Capital Management, adding an estimated $8.73M. The largest seller was AQR Arbitrage, cutting an estimated $4.56M.

  • 59 institutional investors held Aspire Biopharma (ASBP) as of Q3 2022, up from 52 in Q2 2022.
  • Funds reported $260M of Aspire Biopharma stock for Q3 2022, up 7.8% quarter-over-quarter.
  • 11 funds opened new Aspire Biopharma positions in Q3 2022 and 4 closed out, a net change of +7 holders.
  • The largest Aspire Biopharma buyer in Q3 2022 was Highbridge Capital Management, an estimated $8.73M added.
  • The largest Aspire Biopharma seller in Q3 2022 was AQR Arbitrage, an estimated $4.56M sold.

Based on aggregated 13F filings for Q3 2022.